Skip to main content
Bonesupport Holding logo

Bonesupport Holding — Investor Relations & Filings

Ticker · BONEX ISIN · SE0009858152 LEI · 549300COLY053IGTLD63 ST Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2018-11-07 Interim / Quarterly Rep…
Country SE Sweden
Listing ST BONEX

About Bonesupport Holding

https://www.bonesupport.com/en-eu/

Bonesupport Holding is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes. Its core product platform, CERAMENT®, is an innovative range of osteoconductive and drug-eluting products designed to heal bone defects. A key characteristic of CERAMENT® is its ability to remodel into the patient's own host bone, typically within six to twelve months. The products are used to treat bone voids and defects arising from trauma, infection, disease, or related surgical procedures. The radiopaque nature of the material allows for visualization during and after surgery.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report covering the period 1 July – 30 September 2018 and 1 January – 30 September 2018. It includes detailed financial statements (Net Sales, Gross Profit, Operating loss, etc.), management commentary (CEO comment), significant events, and operational updates. It is clearly an interim/quarterly financial report rather than an announcement or a summary. 9M 2018
2018-11-07 English
BONESUPPORT HOLDING AB (publ) – Q3 2018 Interim Report – invitation to conference call and webcast
Report Publication Announcement Classification · 1% confidence The document is titled "BONESUPPORT HOLDINGAB (publ) – Q3 2018 Interim Report – invitation to conference call and webcast". It explicitly states that the Q3 2018 Interim Report will be published on November 7, 2018, and immediately follows this announcement with details about the conference call and webcast to discuss those results. Since the document itself is an invitation/announcement about the upcoming release of the Interim Report and the associated call, and given its short length (3791 characters), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) itself. The key indicator is the focus on announcing *when* the report will be released and providing access details for the follow-up call.
2018-11-01 English
BONESUPPORTs rapport för tredje kvartalet – Inbjudan till telefonkonferens
Report Publication Announcement Classification · 1% confidence The document is titled "BONESUPPORTs rapport för tredje kvartalet – Inbjudan till telefonkonferens" (BONESUPPORT's third-quarter report – Invitation to conference call). It explicitly states that the company will release its interim report for the third quarter of 2018 on November 7, 2018, and immediately follows this by inviting recipients to a conference call and online presentation on the same day at 10:00 CET to discuss the report. The document itself is an announcement about the upcoming release of the report and the associated call details, not the full report (Interim Report, IR) or the transcript of the call (CT). According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement regarding the publication of a report often points to a Report Publication Announcement (RPA). Since this document's primary function is to announce the publication date and host a call about the 'delårsrapport' (interim report), RPA is the most appropriate classification.
2018-11-01 Swedish
BONESUPPORT starts selling CERAMENT® BONE VOID FILLER Direct in the US via its own New Distributor Network
Regulatory Filings Classification · 1% confidence The document is a press release dated October 22, 2018, announcing a strategic business update: BONESUPPORT starting to sell CERAMENT® BONE VOID FILLER Direct in the US via a new distributor network, following the termination of an agreement with Zimmer Biomet. This type of announcement, detailing operational changes, strategic milestones, and commercial updates, is characteristic of an Earnings Release (ER) if it were focused purely on financial results, or a general Regulatory Filing (RNS). However, since it details significant commercial strategy changes and operational achievements (launching a new network, sales expectations), it is most closely aligned with an Earnings Release (ER) which often includes forward-looking statements and operational highlights, or potentially a general Regulatory Filing (RNS) if it doesn't fit the strict definition of an ER (which usually focuses on period-end results). Given the content is a major business update rather than a formal financial statement (like 10-K or IR), and it is not a transcript (CT), presentation (IP), or dividend notice (DIV), it fits best as a general announcement. Since it is a specific, material business update that isn't a standard financial report, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although ER is also plausible if this was released alongside preliminary results. Given the focus on distribution strategy and sales network expansion rather than reported quarterly figures, RNS is safer than ER.
2018-10-22 English
BONESUPPORT börjar sälja CERAMENT® BONE VOID FILLER i USA direkt genom eget distributörsnätverk
Regulatory Filings Classification · 1% confidence The document is a press release dated October 22, 2018, announcing that BONESUPPORT is starting to sell CERAMENT® BVF directly through its own distributor network in the US, following the termination of an exclusive agreement with Zimmer Biomet. It details strategic changes, new distribution agreements, and expected positive effects on sales reports and margins. This type of announcement, detailing operational changes, strategic shifts, and commercial updates, is characteristic of a general corporate announcement or press release. Since it is not a formal regulatory filing like a 10-K, a specific financial report (IR, MRQ), a management discussion (MDA), or a dividend notice (DIV), it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially a Capital/Financing Update (CAP) if the focus was purely on financing, but here the focus is commercial operations. Given the nature of the announcement (a significant operational/commercial update released to the public), RNS is the most appropriate general classification for non-standardized corporate news releases.
2018-10-22 Swedish
BONESUPPORT presenterar CERAMENT® BONE VOID FILLER på två kommande ortopediska kongresser i USA
Regulatory Filings Classification · 1% confidence The document is a press release from BONESUPPORT AB, dated October 8, 2018, announcing their participation in two upcoming orthopedic conferences in the USA to promote their product CERAMENT®|BONE VOID FILLER. It details the conferences, the timing relative to their US distributor network launch, and includes quotes from management and contact information. The final paragraph explicitly states: "Denna information är sådan information som BONESUPPORT HOLDING AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is information that BONESUPPORT HOLDING AB (publ) is obliged to disclose pursuant to the EU's Market Abuse Regulation.) This structure—a formal announcement of material, non-financial business information required for public disclosure under market regulations—fits best under the general 'Regulatory Filings' category (RNS), as it is not a specific financial report (10-K, IR, ER), a management discussion (MDA), or a proxy statement (DEF 14A). It is a general regulatory disclosure.
2018-10-08 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.